Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock‐in mouse model
Open Access
- 9 January 2024
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (3) , 494-508
Abstract
Proteostatic regulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is crucial for maintaining proper brain neurotransmitter homeostasis. Variants of the TH gene are associated with tyrosine hydroxylase deficiency (THD), a rare disorder with a wide phenotypic spectrum and variable response to treatment, which affects protein stability and may lead to accelerated degradation, loss of TH function and catecholamine deficiency. In this study, we investigated the effects of the TH cofactor tetrahydrobiopterin (BH4) on the stability of TH in isolated protein and in DAndifferentiated from iPSCs from a human healthy subject, as well as from THD patients with the R233H variant in homozygosity (THDA) and R328W and T399M variants in heterozygosity (THDB). We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells. To translate this in vitro effect, we treated with BH4 a knock-in THD mouse model with Th variant corresponding to R233H in patients. Importantly, treatment with BH4 significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy). In conclusion, our study demonstrates the stabilizing effects of BH4 on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes. These findings highlight the therapeutic potential of BH4 as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management.Keywords
Funding Information
- Instituto de Salud Carlos III (FIS FI21/00073, Red de Terapia Celular ‐ TerCel RD16/0011/0024)
- European Research Council (2012‐StG‐311736‐PD‐HUMMODEL)
- Ministerio de Economía y Competitividad (RTI2018‐095377‐B‐100 y PID2019‐108792‐GB‐I00)
- Agencia Estatal de Investigación (Unidad de Excelencia María de Maeztu CEX2018‐000792‐M)
- AGAUR (2017‐SGR‐899)
- Generalitat de Catalunya
- Stiftelsen Kristian Gerhard Jebsen
- Fundació la Marató de TV3 (202012‐31, 202012‐32, 202012‐33)
- Ministerio de Universidades (CAS22/00117)
- European Molecular Biology Organization (10326)
This publication has 50 references indexed in Scilit:
- Sapropterin dihydrochloride for the treatment of hyperphenylalaninemiasExpert Opinion on Drug Metabolism & Toxicology, 2013
- Efficient Generation of A9 Midbrain Dopaminergic Neurons by Lentiviral Delivery of LMX1A in Human Embryonic Stem Cells and Induced Pluripotent Stem CellsHuman Gene Therapy, 2012
- Tyrosine hydroxylase and regulation of dopamine synthesisArchives of Biochemistry and Biophysics, 2011
- Expanding Phenotype and Clinical Analysis of Tyrosine Hydroxylase DeficiencyJournal of Child Neurology, 2010
- Repetitive orogastric gavage affects the phenotype of diet-induced obese micePhysiology & Behavior, 2010
- Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylaseJournal of Neurochemistry, 2008
- Effects of mutations in tyrosine hydroxylase associated with progressive dystonia on the activity and stability of the proteinProteins: Structure, Function, and Bioinformatics, 2004
- Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutationsHuman Mutation, 2004
- Conformation and interaction of phenylalanine with the divalent cation at the active site of human recombinant tyrosine hydroxylase as determined by proton NMRBiochemistry, 1993
- Recombinant human tyrosine hydroxylase isozymesEuropean Journal of Biochemistry, 1991